MFA
VRTX icon

McClarren Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

McClarren Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed – – 294
2025
Q1 		$0 Buy
+1
New +$466 ﹤0.01% 371
2024
Q4 		– Sell
-1
Closed – – 315
2024
Q3 		$0 Sell
1
-467
-100% -$224K ﹤0.01% 360
2024
Q2 		$0 Buy
468
+467
+46,700% +$203K ﹤0.01% 375
2024
Q1 		$1K Hold
1
– – ﹤0.01% 343
2023
Q4 		$0 Hold
1
– – ﹤0.01% 425
2023
Q3 		$0 Hold
1
– – ﹤0.01% 407
2023
Q2 		$0 Hold
1
– – ﹤0.01% 477
2023
Q1 		$0 Hold
1
– – ﹤0.01% 470
2022
Q4 		$0 Buy
+1
New +$305 ﹤0.01% 480

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

McClarren Financial Advisors's VRTX Position: Q2 2025 in Review

McClarren Financial Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 1 share.

McClarren Financial Advisors first reported a position in VRTX in Q4 2022 and held it in 9 quarters. The position peaked at $1K in Q1 2024. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • McClarren Financial Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • McClarren Financial Advisors sold 1 Vertex Pharmaceuticals share in Q2 2025.
  • McClarren Financial Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 9 quarters.
  • McClarren Financial Advisors's Vertex Pharmaceuticals position peaked at $1K in Q1 2024.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on McClarren Financial Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.